Literature DB >> 33834274

Pro- and anti-inflammatory adipokines are associated with cardiometabolic risk markers in Brazilian schoolchildren.

Mariana De Santis Filgueiras1, Milene Cristine Pessoa2, Josefina Bressan3, Fernanda Martins de Albuquerque3, Lara Gomes Suhett3, Mariane Alves Silva3, Juliana Farias de Novaes3.   

Abstract

Pro- and anti-inflammatory adipokines have been regarded as potential markers of obesity and cardiometabolic comorbidities. However, few studies have evaluated this association in children. We aimed to evaluate the relationship between adipokine concentrations and cardiometabolic risk markers in Brazilian schoolchildren. This was a cross-sectional study with 378 children aged 8-9 years from Viçosa, Minas Gerais, Brazil. We measured adipokines (leptin, retinol-binding protein 4, adiponectin, and chemerin) and cardiometabolic risk markers (fasting glucose, HOMA-IR, lipid profile, and blood pressure). Cardiometabolic risk markers were compared by quintiles of adipokines with linear regression adjusted for potential confounders. Leptin was positively associated with diastolic blood pressure (P = 0.03) and HOMA-IR (P = 0.01), and retinol-binding protein 4 was positively associated with total cholesterol (P = 0.04). Each standard deviation of leptin and retinol-binding protein 4 was associated to, respectively, a 0.1 (95%CI: 0.1; 0.2), 0.3 (95%CI: 0.1; 0.6), and 2.5 (95%CI: 0.1; 4.9) units increase in diastolic blood pressure, HOMA-IR, and total cholesterol. Adiponectin was negatively associated with diastolic blood pressure (P = 0.01) and HOMA-IR (P = 0.01), and chemerin was negatively associated with glucose (P = 0.001). Each standard deviation of adiponectin and chemerin was associated to, respectively, a -0.1 (95%CI: -0.2; -0.1), -0.2 (95%CI: -0.3; -0.1), and -1.2 (95%CI: -1.9; -0.5) units decrease in diastolic blood pressure, HOMA-IR, and glucose.
Conclusion: Pro- and anti-inflammatory adipokines were positively and negatively associated with cardiometabolic risk markers, respectively, among schoolchildren, indicating this relationship may be identified at earlier ages. What is Known: • Although leptin, retinol-binding protein 4, and adiponectin are well-known adipokines, a consensus regarding their relationship with cardiometabolic risk markers, especially in schoolchildren, has not yet been reached. • Chemerin is an adipokine that has been studied recently. Yet, due to its dependence on the target cell type, its functions are still a controversial topic. What is New: • Leptin was positively associated with diastolic blood pressure and HOMA-IR, and retinol-binding protein 4 was positively associated with total cholesterol. • Adiponectin was negatively associated with diastolic blood pressure and HOMA-IR, and chemerin was negatively associated with glucose.

Entities:  

Keywords:  Adipokines; Adiposity; Blood pressure; Dyslipidemias; Inflammation; Insulin resistance

Year:  2021        PMID: 33834274     DOI: 10.1007/s00431-021-04040-z

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  43 in total

Review 1.  Adipose tissue expandability in the maintenance of metabolic homeostasis.

Authors:  Sarah L Gray; Antonio J Vidal-Puig
Journal:  Nutr Rev       Date:  2007-06       Impact factor: 7.110

2.  Chemerin as a mediator between obesity and vascular inflammation in children.

Authors:  Kathrin Landgraf; Daniela Friebe; Tina Ullrich; Jürgen Kratzsch; Kathrin Dittrich; Gunda Herberth; Volker Adams; Wieland Kiess; Sandra Erbs; Antje Körner
Journal:  J Clin Endocrinol Metab       Date:  2012-03-21       Impact factor: 5.958

3.  Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity.

Authors:  Christine Frithioff-Bøjsøe; Morten A V Lund; Ulrik Lausten-Thomsen; Paula L Hedley; Oluf Pedersen; Michael Christiansen; Jennifer L Baker; Torben Hansen; Jens-Christian Holm
Journal:  Pediatr Diabetes       Date:  2019-12-26       Impact factor: 4.866

4.  Leptin and cardiometabolic risk factors in obese children and adolescents.

Authors:  Nathalia C Gonzaga; Carla C M Medeiros; Danielle F de Carvalho; João G B Alves
Journal:  J Paediatr Child Health       Date:  2014-06-13       Impact factor: 1.954

5.  Association between plasma leptin and blood pressure in two population-based samples of children and adolescents.

Authors:  Anders Grøntved; Jostein Steene-Johannessen; Iben Kynde; Paul W Franks; Jørn Wulf Helge; Karsten Froberg; Sigmund A Anderssen; Lars Bo Andersen
Journal:  J Hypertens       Date:  2011-06       Impact factor: 4.844

6.  Retinol-binding protein 4 and insulin resistance are related to body fat in primary and secondary schoolchildren: the Ouro Preto study.

Authors:  Ana Paula Pereira Castro; Ana Paula Carlos Cândido; Roney Luiz de Carvalho Nicolato; Ivo Santana Caldas; George Luiz Lins Machado-Coelho
Journal:  Eur J Nutr       Date:  2013-06-14       Impact factor: 5.614

7.  Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children.

Authors:  Mehmet Boyraz; Ferhat Cekmez; Abdulbaki Karaoğlu; Peyami Cinaz; Mustafa Durak; Aysun Bideci
Journal:  Biomark Med       Date:  2013-06       Impact factor: 2.851

Review 8.  Adipokine dysregulation and adipose tissue inflammation in human obesity.

Authors:  Xabier Unamuno; Javier Gómez-Ambrosi; Amaia Rodríguez; Sara Becerril; Gema Frühbeck; Victoria Catalán
Journal:  Eur J Clin Invest       Date:  2018-08-03       Impact factor: 4.686

9.  Proinflammatory cytokines and leptin are increased in serum of prepubertal obese children.

Authors:  A Denizmen Aygun; Serdal Gungor; Bilal Ustundag; Metin K Gurgoze; Yasar Sen
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

10.  Cardiovascular Risk in Children: Focus on Pathophysiological Aspects.

Authors:  Simonetta Genovesi; Gianfranco Parati
Journal:  Int J Mol Sci       Date:  2020-09-10       Impact factor: 5.923

View more
  1 in total

Review 1.  Chemerin as Potential Biomarker in Pediatric Diseases: A PRISMA-Compliant Study.

Authors:  Katarzyna Zdanowicz; Anna Bobrus-Chociej; Dariusz Marek Lebensztejn
Journal:  Biomedicines       Date:  2022-03-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.